

DRUG UTILIZATION REVIEW BOARD MEETING
Wednesday, October 16, 2019

Agenda

MO Coalition for Community Behavioral Healthcare
Lower Level CEO Room,
221 Metro Drive, Jefferson City, MO

- *Welcome, Announcements and Minutes Review* 10:00-10:05 AM
(Susan Abdel-Rahman)
- *Pharmacy Program/Budget Update* 10:05-10:30 AM
(Elizabeth Short)
- *Review of Prior Authorization Meeting and* 10:30-10:40 AM
Public Hearing (Josh Moore)

A. Clinical Edits 10:40-11:30 AM

- I. **BiDil Clinical Edit**
- II. **Botulinum Toxin Clinical Edit**
- III. **Diacomit Clinical Edit**
- IV. **Duchenne Muscular Dystrophy (DMD) Clinical Edit**
- V. **Emsam Clinical Edit**
- VI. **Lambert-Eaton Myasthenic Syndrome(LEMS) Clinical Edit**
- VII. **Narcolepsy Inhibitors Clinical Edit**
- VIII. **Oxandrin Clinical Edit**
- IX. **Psychotropic Medications Polypharmacy Clinical Edit**
- X. **Ranexa Clinical Edit**
- XI. **SNRI Clinical Edit**
- XII. **SSRI Clinical Edit**
- XIII. **Synagis Clinical Edit**
- XIV. **Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit**
- XV. **Zolgensma Clinical Edit**
- XVI. **Zometa Clinical Edit**

B. Preferred Drug List (PDL) 11:30-12:30 AM

- XVII. **ACE Inhibitors/Calcium Channel Blocker Combination Agents**
- XVIII. **ACE Inhibitors and ACE Inhibitors Diuretic Combination Agents**
- XIX. **ADHD – Amphetamines – Short Acting Agents**
- XX. **ADHD – Methylphenidate – Long Acting Agents**
- XXI. **ADHD – Methylphenidate – Short Acting Agents**
- XXII. **ADHD – Amphetamines – Long Acting Agents**
- XXIII. **ADHD – Non-stimulant Agents**
- XXIV. **ARB and ARB Diuretic Combination Agents**
- XXV. **Angiotensin II Receptor/Calcium Channel Blocker Combination Agents**
- XXVI. **Anticoagulant Agents: Oral and Subcutaneous**
- XXVII. **Antiplatelet Agents**

- XXVIII. **Beta Adrenergic Blocker and Beta Adrenergic Blocker Diuretic Combination Agents**
- XXIX. **Calcium Channel Blocker Agents (Dihydropyridines)**
- XXX. **Calcium Channel Blocker Agents (Non-Dihydropyridines)**
- XXXI. **Direct Renin Inhibitors and Direct Renin Inhibitors Combination Agents**
- XXXII. **Dry Eye Disease Agents - NEW**
- XXXIII. **Lipotropic Agents: Homozygous Familial Hypercholesterolemia Products**
- XXXIV. **Lipotropic Agents: Niacin Derivatives**
- XXXV. **Lipotropic Agents: Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors**
- XXXVI. **Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products**
- XXXVII. **Lipotropic Agents: Triglyceride Lowering Agents**
- XXXVIII. **Proton Pump Inhibitor Agents**
- XXXIX. **Pulmonary Arterial Hypertension (PHA) Agents: Inhaled/Injectable**
- XL. **Pulmonary Arterial Hypertension (PHA) Agents: Oral Endothelin Receptor Antagonists (ETRA)s**
- XLI. **Pulmonary Arterial Hypertension (PHA) Agents: Oral Phosphodiesterase-5 (PDE5) Inhibitors and Soluble Guanylate Cyclase (SCG) Stimulators**
- XLII. **Pulmonary Arterial Hypertension (PHA) Agents: Oral Prostacyclin Pathway Agonists**
- XLIII. **Sympatholytic Antihypertensive Agents**

- *Lunch* 12:30-1:00 PM
- *Conduent Update* 1:00-1:30 PM
(Luke Boehmer)
- *Other Business* 1:30-2:00 PM
(Luke Boehmer)
 - *“Top 25” Drugs*
 - *Profile Updates*
 - *DUR Report*
 - *Clinical Edit Summary Report*
 - *Call Center Statistics*
 - *Program Utilization Information*
- *Move to close under Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*

Executive Session

- *Patient Profile Reviews* 2:00-3:00 PM

***At the discretion of the chairperson informal comments may be accepted from members of the audience at various points on the agenda. Times noted are approximate. Agenda items may move more quickly.*